Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of <i>Helicobacter pylori</i> in a developing country

Ahuja, Vineet; Dhar, Anita; Bal, Chandrasekhar; Sharma, Manish

doi:10.1046/j.1365-2036.1998.00338.x

Cited by 33 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, alternative regimens that overcome bacterial resistance to standard antibiotics and reduce the incidence of side effects have been evaluated. In recent years new treatment schemes based on fluoroquinolones (levofloxacin or moxifloxacin plus an antibiotic and a PPI) have been under investigation, either as the first line or as rescue therapies [9][10][11][12]; however, first-generation fluoroquinolones such as norfloxacin and pefloxacin did not show satisfactory eradication rates [24,25]. Several studies have evaluated the efficacy of different levofloxacin-based triple therapies (associated with rabeprazole and amoxicillin or nitroimidazole) and shown eradication rates up to 90% [9,10].…”

Section: Discussionmentioning

confidence: 99%

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

Bago

Včev

Tomić

et al. 2007

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

Bago

Včev

Tomić

et al. 2007

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…Another Indian study compared three different regimens, containing a PPI, secnidazole, a nitroimidazole, and clarithromycin, amoxicillin or pefloxacin, an analog of norfloxacin not approved by the Food and Drug Administration. The combination with pefloxacin achieved an eradication success of 71% [Ahuja et al 1998]. …”

Section: Introductionmentioning

confidence: 99%

Should quinolones come first in Helicobacter pylori therapy?

Berning

Krasz

Miehlke

2010

Therap Adv Gastroenterol

View full text Add to dashboard Cite

New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been successfully introduced into the treatment of Helicobacter pylori infection. Based on a large body of evidence, current guidelines recommend the use of levofloxacin-or moxifloxacincontaining proton-pump inhibitor (PPI) triple therapies in second-line or rescue treatment of H. pylori infection. The efficacy of standard PPI triple therapies has substantially declined during the last decade, mainly due to increasing resistance against the key antibiotics clarithromycin and metronidazole. Therefore, alternative strategies for first-line therapy of H. pylori infection have been evaluated in a considerable number of clinical trials including sequential regimens, nonbismuth quadruple regimens, and quinolone-containing PPI triple therapy regimens. The aim of this paper is to summarize the current body of evidence of levofloxacin-and moxifloxacin-containing regimens in first-line treatment of H. pylori infection, and to discuss the risks and benefits of these strategies in the light of increasing resistance of H. pylori to quinolones.

show abstract

“…In recent years new treatment schemes based on fluoroquinolones have been under investigation (21)(22)(23)(24)(25)(26)(27)(28)(29); however, first-generation fluoroquinolones such as norfloxacin and pefloxacin did not show satisfactory eradication rates (30,31). Several studies have evaluated the efficacy of different levofloxacin-based triple therapies and shown eradication rates up to 90% (22,27).…”

Section: Introductionmentioning

confidence: 99%

Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials

Wang

Yang

et al. 2009

Intern. Med.

View full text Add to dashboard Cite

Background Moxifloxacin-based (RR, 1.13; 95% CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95% CI, 0.25, 1.48; P<0.28). Conclusions Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.

show abstract

Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country

Abstract: High H. pylori eradication rates were achieved using the amoxycillin- and clarithromycin-based therapies. Fewer side-effects, better compliance and low cost favoured the amoxycillin-based therapy.

Cited by 33 publications

References 15 publications

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

Should quinolones come first in Helicobacter pylori therapy?

Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About